Trial Profile
Phase 1b & 2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (VIRO-15)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 31 May 2023
Price :
$35
*
At a glance
- Drugs Olvimulogene nanivacirepvec (Primary) ; Antineoplastics; Bevacizumab; Carboplatin
- Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Acronyms VIRO-15
- Sponsors Genelux Corporation
- 25 May 2023 Primary endpoint (Overall Response Rate (ORR) by RECIST 1.1 (Phase 2)) has been met, according to a Genelux Corporation media release.
- 25 May 2023 According to a Genelux Corporation media release, topline results of this study published in JAMA Oncology.
- 25 May 2023 Results presented in a Genelux Corporation Media Release